Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
197 Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells
Compose a Response to This Article
Other responses
No responses have been published for this article.